Peptides are gathering significant attention not only for their affinity and specificity towards a diverse array of target proteins but also for their tissue permeability (oral suitability) and ease of chemical synthesis. Notably, cyclic peptides that incorporate unnatural amino acids are expected as PPI inhibitors. Additionally, they are anticipated to act as DDS ligands, facilitating the delivery of nucleic acid-based medicines and other drugs to targeted tissues/cells due to their exceptional binding affinity and stability.
The Fujifilm Group offers a comprehensive suite of contract services. Our core offerings are the use of mRNA display technology to acquire peptides with strong, specific binding to target proteins, coupled with expedited structural optimization activity screening and of these hit peptides (e.g., inhibition activity, selectivity). Additionally, we provide supporting services such as peptide chemical synthesis and the preparation of target proteins.
We receive target proteins*1 from the customer and return the structural information of the acquired peptides.
- *1 Required target protein: 0.1~0.5 mg, >90% in purity
- Innovative improvements in mRNA display enable screening from >1013 peptides.
- Practical biosynthesis & assays enable rapid selection and activity explorations.
Peptides with wide varieties and high-affinities(~nM) can be obtained with high success rate (If you are interested in details of our track records, please feel free to contact us.).
Cyclic peptides with unnatural amino acids have the following characteristics:
- Wide binding capacity and high specificity to undruggable targets.
- Higher stability, lower immunogenicity, and higher tissue permeability than antibodies.
- Being able to be chemically synthesized and be conjugated to other molecules. （CMC difficulty is also low.）
Cyclic peptides are expected in various drug candidates due to their unique characteristics.
- Improved mRNA display allows screening from a huge library.
- Many conditions (=cycle size, targets, selections) can be performed in parallel.
A variety of hits have been obtained with a high success rate.
Rapid selection and activity exploration by practical biosynthesis & assay combined with conventional chemical synthesis.
Chemical Synthesis: long lead time (20~30days) and not suited parallel synthesis/purification.
Biosynthesis: short lead time (5~7days) and suited for parallel preparation (~1,000 peptides/month)
Hit peptides have been obtained toward >20 targets with our platform.
High binding affinity were achieved as the Hits in initial screening.
Diverse binding peptides were successfully obtained toward both of 2 FGFRs (fibroblast growth factor receptor).
- FGFR activatable peptide had been found through rapid and exhaustive cell activity screening with biosynthetic peptides from diverse hit peptides.
- Optimized peptide showed same cell growth rate with the natural protein (bFGF) in MSC (Mesenchymal Stem Cell).
- siRNAs were conjugated to the integrin αvβ3-binding peptide. With this Peptide Oligonucleotide Conjugates, cell-selective target gene knockdown were achieved.
- Peptide Discovery Platform for Advancing Peptide-Oligonucleotide Conjugation (Yukiko Ishii, Shin Izuta, Masahiro Kochi, Koo Suzuki)
- Peptide Discovery Platform for Advancing Peptide-Oligonucleotide Conjugation (Yukiko Ishii, Shin Izuta, Masahiro Kochi, Koo Suzuki)
- Cyclic Peptide Discovery Services (Yukiko Ishii, Shin Izuta, Ryota Haba)